Zealand Pharma A/S :Zealand Pharma Announces Positive Topline Results From 13-Week Phase 1B Multiple Ascending Dose Clinical Trial With Glp-1/Glp-2 Receptor Dual Agonist Dapiglutide.Zealand Pharma A/S - Placebo-Adjusted Reductions In Body Weight Of Up To A Mean Of 8.3% With Dapiglutide After 13 Weekly Doses.Zealand Pharma A/S - Dapiglutide Treatment Up To 13 Mg Safe And Well-Tolerated.Zealand Pharma A/S - Higher Doses Up To 26 Mg Being Evaluated, Results Expected H1 2025.Zealand Pharma A/S - To Initiate Phase 2B Trial For Dapiglutide In H1 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments